His research is directed toward improving the integration of genetic information into the clinical management of women with breast cancer. He and his colleagues have conducted a number of studies examining outcomes in women with hereditary breast cancer to better define the risks and benefits of treatments such as breast conserving therapy and adjuvant chemotherapy in this group. He is currently conducting studies to evaluate the impact of intensive screening or surgical prevention upon women's quality of life and to develop new screening tools for breast cancer, such as serum peptide profiling.